Metastasis Directed Therapy- JAMA Oncol 2026

Metastasis-Directed Therapy (MDT) Overview:

MDT refers to localised treatments aimed specifically at metastatic lesions in patients with cancer. These therapies include techniques such as stereotactic body radiotherapy (SBRT), surgical resection, and thermal ablations (e.g., radiofrequency or cryoablation). MDT is particularly valuable for patients with oligometastatic disease, where the number of metastases is limited and potentially treatable.

Utility in Metastatic Disease:

MDTs have redefined the therapeutic approach to metastatic cancer by offering the possibility of long-term disease control or even cure in select patients. Rather than focusing solely on systemic therapies, MDT targets visible metastatic lesions, suppressing prometastatic signalling and disrupting interlesional communication. Clinical evidence suggests that MDT can delay systemic therapy initiation, extend progression-free survival, and improve overall outcomes when applied iteratively or comprehensively.

Emerging research highlights the importance of treating all visible disease to prevent reseeding and progression. MDT's effectiveness is influenced by factors such as tumour biology, immune phenotype, and metastatic kinetics, underscoring the need for personalised strategies. MDT represents a shift toward transforming metastatic cancer into a manageable or potentially curable condition.